Skip to main content

Warum Larventherapie – Referenzen

  1. Mudge E, Price P, Walkley N, and Harding K. 2014. A randomized controlled trial of larval therapy for the debridement of leg ulcers: results of a multicenter, randomized, controlled, open, observer blind, parallel group study. Wound Repair & Regeneration, Jan-Feb, 22(1); 43-51.
  2. Bennett H. et al. 2013. Cost-Effectiveness of Interventions for Chronic Wound Debridement; an Evaluation in Search of Data. London: Wounds UK 2013; 9(4) Suppl.
  3. Gilead L, Mumcuoglu KY, Ingber A. The use of maggot debridement therapy in the treatment of chronic wounds in hospitalized and ambulatory patients. J Wound Care. 2012;21(2):78-85.
  4. van der Plas MJA, Baldry M, Van Dissel JT, et al. 2009. Maggot secretions suppress pro-inflammatory responses of human monocytes through elevation of cyclic AMP. Diabetologia 52: 1962-70.
  5. Cazander G., et al. 2009. Maggot therapy for wound healing: clinical relevance, mechanisms of action and future prospects. Journal Wound Technology, 5: pp.18-23.
  6. Cowan  LJ, Stechmiller JK, Phillips  P, Yang Q, et al., 2013. Chronic wounds, biofilm and use of medicinal larvae. Ulcers; 487024.
  7. Schultz GS, Sibbald R, Falanga V, et al. 2003. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen; 11: S1-28 Suppl.
  8. Pritchard, D.I., Čeřovský, V., Nigam, Y., Pickles, S.F., Cazander, G., Nibbering, P.H., Bültemann, A. and Jung, W. (2016), TIME management by medicinal larvae. Int Wound J, 13: 475-484. https://doi.org/10.1111/iwj.12457
  9. Antibakterielle Wirkung von Fliegenmaden (L. sericata) in vitro. In-vitro bactericidal activity of maggots of the green blowfly (Lucilia sericata). Skin Pharmacol Physiol 2007;20:112–115, 2006. Georg Daeschlein1, Britta Hoffmeister1, Harald Below1, Axel Kramer1*.
  10. Andersen AS, Sandvang D, Schnorr KM, Kruse T, Neve S, Joergensen B, Karlsmark T, Krogfelt KA. A novel approach to the antimicrobial activity of maggot Débridement therapy. J Antimicrob Chemother. 2010;65(8):1646-54.
  11. Die Kosteneffektivität der Larventherapie in Deutschland